Paula Cobb
Direktor/Vorstandsmitglied bei PROTHENA CORPORATION PLC
Vermögen: - $ am 30.04.2024
Profil
Paula K.
Cobb is an Independent Director at Prothena Corp.
Plc, a Director at NightstaRx Ltd., and the Chief Business Officer at Affinia Therapeutics, Inc. She was previously an Independent Non-Executive Director at Nightstar Therapeutics Ltd., the Senior Vice President-Rare Disease Group at Biogen, Inc., and the Chief Operating Officer at Decibel Therapeutics, Inc. Cobb received her undergraduate degree from Amherst College and her MBA from Harvard Business School.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
PROTHENA CORP. PLC
-.--% | 04.03.2024 | 0 ( -.--% ) | - $ | 30.04.2024 |
Aktive Positionen von Paula Cobb
Unternehmen | Position | Beginn |
---|---|---|
PROTHENA CORPORATION PLC | Direktor/Vorstandsmitglied | 01.07.2019 |
NightstaRx Ltd.
NightstaRx Ltd. Medical/Nursing ServicesHealth Services NightstaRx Ltd. develops and commercializes therapies for retinal dystrophies. It offers retinal gene therapy that provides one-time cure for choroideremia (a rare inherited cause of blindness) and other retinal dystrophies. The company was founded by Robert MacLaren, Miguel Seabra, and Matthew During in January 2014 and is headquartered in London, the United Kingdom. | Direktor/Vorstandsmitglied | - |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | Corporate Officer/Principal | 01.09.2020 |
Ehemalige bekannte Positionen von Paula Cobb
Unternehmen | Position | Ende |
---|---|---|
DECIBEL THERAPEUTICS, INC. | Geschäftsführer | 01.12.2019 |
NIGHTSTAR THERAPEUTICS PLC | Direktor/Vorstandsmitglied | 07.06.2019 |
BIOGEN INC. | Corporate Officer/Principal | 01.01.2016 |
Ausbildung von Paula Cobb
Amherst College | Undergraduate Degree |
Harvard Business School | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 3 |
---|---|
DECIBEL THERAPEUTICS, INC. | Health Technology |
PROTHENA CORPORATION PLC | Health Technology |
BIOGEN INC. | Health Technology |
Private Unternehmen | 3 |
---|---|
Nightstar Therapeutics Ltd.
Nightstar Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Nightstar Therapeutics Ltd. is a clinical-stage gene therapy. It engages in the development and commercialization of novel one-time treatments for patients suffering from rare inherited retinal diseases. The company was founded by Robert MacLaren, Miguel Seabra and Matthew During in 2014 and is headquartered in London, the United Kingdom. | Health Technology |
NightstaRx Ltd.
NightstaRx Ltd. Medical/Nursing ServicesHealth Services NightstaRx Ltd. develops and commercializes therapies for retinal dystrophies. It offers retinal gene therapy that provides one-time cure for choroideremia (a rare inherited cause of blindness) and other retinal dystrophies. The company was founded by Robert MacLaren, Miguel Seabra, and Matthew During in January 2014 and is headquartered in London, the United Kingdom. | Health Services |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | Health Technology |